Autoantibodies against complement proteins in patients with antiphospholipid syndrome: Prevalence and clinical associations-Reference-Cited by-同舟云学术

Autoantibodies against complement proteins in patients with antiphospholipid syndrome: Prevalence and clinical associations

Published:2024-05-03 Issue:7 Volume:54 Page:
ISSN:0014-2980
Container-title:European Journal of Immunology
language:en
Short-container-title:Eur J Immunol

Author:

Philip Rémi¹²³^ORCID,Aouba Achille¹³,Martin Silva Nicolas¹,Mariotte Delphine⁴,Hamidi Houcine²⁵,Rhouni Sanae⁵^ORCID,Darnige Luc⁶,Dragon‐Durey Marie‐Agnès²⁵

Affiliation:

1. Department of Clinical Immunology and Internal Medicine CHU of Caen Normandie Caen France

2. INSERM UMRS 1138 Team "Inflammation Complement and Cancer" Centre de Recherche des Cordeliers Sorbonne Université Université Paris Cité Paris France

3. UNICAEN CHU de Caen Normandie, Normandie University Caen France

4. Laboratory of Immunology and Histocompatibility Department of Biology CHU of Caen Normandie Caen France

5. Laboratory of Immunology Hôpital Européen Georges‐Pompidou Assistance Publique Hopitaux de Paris (APHP) Paris France

6. Hematology Department Hôpital Européen Georges‐Pompidou Assistance Publique Hôpitaux de Paris Centre‐Université de Paris (APHP‐CUP) Université Paris Cité Innovative Therapies in Haemostasis INSERM UMR‐S1140 Paris France

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/eji.202350832

Reference10 articles.

1. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients

2. Complement and thrombosis in the antiphospholipid syndrome

3. Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome

4. Autoantibodies against a complement component 1 q subcomponent contribute to complement activation and recurrent thrombosis/pregnancy morbidity in anti-phospholipid syndrome

5. Some Anticardiolipin Antibodies Recognize a Combination of Phospholipids With Thrombin-Modified Antithrombin, Complement C4b-Binding Protein, and Lipopolysaccharide Binding Protein